LON:AZN AstraZeneca (AZN) Share Price, News & Analysis £103.86 -98.00 (-0.93%) As of 12:41 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsDividendHeadlinesInsider TradesSustainabilityBuy This Stock About AstraZeneca Stock (LON:AZN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AstraZeneca alerts:Sign Up Key Stats Today's Range£103.64▼£105.0850-Day Range 9,669.50▼£116.0852-Week Range 9,573.51▼£133.88Volume1.21 million shsAverage Volume15.29 million shsMarket Capitalization£199.83 billionP/E Ratio28.47Dividend Yield2.25%Price TargetGBX 6,303.50Consensus RatingModerate Buy Company OverviewAstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @AstraZeneca.Read More… AstraZeneca Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks19th Percentile Overall ScoreAZN MarketRank™: AstraZeneca scored higher than 19% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.3 / 5Analyst RatingModerate Buy Consensus RatingAstraZeneca has received a consensus rating of Moderate Buy. The company's average rating score is 2.60, and is based on 3 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageAstraZeneca has only been the subject of 2 research reports in the past 90 days.Read more about AstraZeneca's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of AstraZeneca is 28.47, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 24.84.Price to Earnings Ratio vs. SectorThe P/E ratio of AstraZeneca is 28.47, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 26.89.Price to Earnings Growth RatioAstraZeneca has a PEG Ratio of 0.86. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioAstraZeneca has a P/B Ratio of 3.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for AZN. Dividend1.7 / 5Dividend StrengthWeak Dividend YieldAstraZeneca pays a meaningful dividend of 1.23%, higher than the bottom 25% of all stocks that pay dividends.Dividend GrowthAstraZeneca does not have a long track record of dividend growth.Dividend CoverageThe dividend payout ratio of AstraZeneca is 64.14%. This payout ratio is at a healthy, sustainable level, below 75%.Read more about AstraZeneca's dividend. Sustainability and ESG4.0 / 5Environmental Score-2.35 Short InterestThere is no current short interest data available for AZN. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for AstraZeneca this week, compared to 3 articles on an average week.Search InterestOnly 14 people have searched for AZN on MarketBeat in the last 30 days. This is a decrease of -18% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, AstraZeneca insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.04% of the stock of AstraZeneca is held by insiders.Percentage Held by Institutions51.03% of the stock of AstraZeneca is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about AstraZeneca's insider trading history. Receive AZN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AstraZeneca and its competitors with MarketBeat's FREE daily newsletter. Email Address AZN Stock News HeadlinesAstraZeneca wins EU backing for Imfinzi in bladder cancerMay 28 at 12:23 AM | msn.comAstraZeneca climbs Friday, outperforms marketMay 16, 2025 | marketwatch.comA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again. May 28, 2025 | Porter & Company (Ad)Is AstraZeneca (AZN) the Best Pharma Stock to Invest in Amid the Domestic Manufacturing Boom?May 13, 2025 | msn.comWhy did the AstraZeneca share price just fall, and what should we do?May 12, 2025 | msn.comAstraZeneca Reports Positive Data From Cancer Drug Trial: Retail Sentiment BrightensMay 9, 2025 | msn.comAstraZeneca advances Friday, outperforms marketMay 9, 2025 | marketwatch.comAstraZeneca slides Wednesday, underperforms marketMay 7, 2025 | marketwatch.comSee More Headlines AZN Stock Analysis - Frequently Asked Questions How have AZN shares performed this year? AstraZeneca's stock was trading at £104.68 at the start of the year. Since then, AZN stock has decreased by 0.8% and is now trading at £103.86. View the best growth stocks for 2025 here. How do I buy shares of AstraZeneca? Shares of AZN stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What other stocks do shareholders of AstraZeneca own? Based on aggregate information from My MarketBeat watchlists, some other companies that AstraZeneca investors own include GSK (GSK), NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Intel (INTC), Advanced Micro Devices (AMD) and Johnson & Johnson (JNJ). Industry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Drug Manufacturers - General Sub-IndustryPharmaceutical Products Current SymbolLON:AZN CIKN/A Webwww.astrazeneca.com Phone+44-20-73045000FaxN/AEmployees83,500Year FoundedN/APrice Target and Rating Average Stock Price TargetGBX 6,303.50 High Stock Price Target£140 Low Stock Price TargetGBX 74 Potential Upside/Downside-39.3%Consensus RatingModerate Buy Rating Score (0-4)2.60 Research Coverage5 Analysts Profitability EPS (Most Recent Fiscal Year)GBX 364.83 Trailing P/E Ratio28.47 Forward P/E Ratio14.23 P/E Growth0.86Net Income£8.71 billion Net Margins13.01% Pretax MarginN/A Return on Equity17.76% Return on Assets7.68% Debt Debt-to-Equity Ratio73.83 Current Ratio0.93 Quick Ratio0.59 Sales & Book Value Annual Sales£66.95 billion Price / Sales2.98 Cash FlowGBX 267.06 per share Price / Cash Flow38.89 Book ValueGBX 2,630 per share Price / Book3.95Miscellaneous Outstanding Shares1,924,030,520Free FloatN/AMarket Cap£199.83 billion OptionableNot Optionable Beta0.17 The Best Nuclear Energy Stocks to BuyNuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.Get This Free Report This page (LON:AZN) was last updated on 5/28/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredTrump Predicts Dollar DownfallREAD THIS VERY CAREFULLY: If you have $100,000 or more saved for retirement, this may make you VERY angry... ...Augusta Precious Metals | SponsoredElon’s 2025 Silver Crisis (What It Means for You)Elon Musk is back in the spotlight—this time for fueling a global scramble for silver. Tesla's relentless p...GoldenCrest Metals | SponsoredF1 Engineering Powers This Electric Marine MotorThe future of marine propulsion has arrived - powered by F-1 grade engineering. In collaboration with McLar...The Tomorrow Investor | SponsoredTrump Quietly Planning $15 Trillion Crypto ShockerMost investors are still unaware, but I believe a new White House action may have quietly opened the floodgate...Paradigm Press | SponsoredUrgent: Make this trade before you hit your pillow tonight… Most people waste 8 hours every night… And 227,916 hours in their lifetime… Dreaming about the life they...Timothy Sykes | SponsoredThe biggest threat isn’t ChinaWhile the headlines focus on AI models and chip speed, Elon Musk is investing in the material side of the stor...True Market Insiders | SponsoredBig Oil’s big pivotThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AstraZeneca PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share AstraZeneca With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.